Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:SIBN

SiBone Q3 2026 Earnings Date & Estimates

SiBone logo
$20.03 -0.07 (-0.35%)
As of 01:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SiBone is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from SiBone in Q3 2026

SiBone is expected to post earnings of -$0.13 per share on revenue of $55.32 million. In the same quarter a year earlier SiBone reported -$0.11 per share on revenue of $48.66 million. SiBone last reported on August 3, 2026, posting -$0.09 per share and beating the -$0.1495 consensus estimate. SiBone has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.13
Expected Revenue
$55.32 million
Prior-Year EPS
-$0.11
Prior-Year Revenue
$48.66 million
Expected Revenue Growth
+13.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.09 (Beat by +$0.0595)
Last Quarter Revenue
$56.01 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

SiBone Q3 2026 Earnings FAQ

SiBone (NASDAQ:SIBN) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

SiBone's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect SiBone to post earnings of -$0.13 per share for Q3 2026.

The consensus revenue estimate for SiBone is $55.32 million for Q3 2026.

SiBone Earnings Headlines

Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued
October 12 at 10:00 PM  |  gurufocus.comhttps://www.gurufocus.com/news/9120211/is-sibone-inc-sibn-overvalued-after-38-rally-gf-value-says-overvalued
SiBone (NASDAQ:SIBN) and Nexalin Technology (NASDAQ:NXL) Financial Contrast
October 12 at 5:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109986
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
October 13 at 1:00 AM  |  InvestorPlace (Ad)
SiBone (NASDAQ:SIBN) Stock: Insider Anshul Maheshwari Sells 3,318 Shares
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099136
SiBone (NASDAQ:SIBN) Stock: Insider Michael Pisetsky Sells 3,133 Shares
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099132
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx, Extending Its Compromised Bone Franchise Beyond the Pelvis
September 29, 2026  |  marketscreener.comM
See More SiBone Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SiBone? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SiBone and other key companies, straight to your email.

About SiBone

SI-BONE, Inc. is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint. SI-BONE also offers products such as iFuse-3D, iFuse-TORQ and the iFuse Bedrock Granite system, which is designed for sacroiliac joint fusion in connection with certain adult lumbopelvic fusion procedures. The company provides associated surgical instruments and procedural technologies for use by spine and orthopedic surgeons.

SI-BONE was founded in 2008 and is headquartered in Santa Clara, California. The company markets its products primarily through a direct sales organization and distributors in the United States and select international markets. Its shares began trading publicly on the Nasdaq under the symbol “SIBN” in 2018.

View SiBone Profile
Earnings Tools